✦ LIBER ✦

A phase I trial evaluating the safety and immunogenicity of a HER-2 protein vaccine in patients with breast cancer

✍ Scribed by B Overmoyer; A Brufsky; B Volck; D Leach; A Oestergaard

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Clinical and Immunologic Responses of HL

✍ Ritesh Patil; Guy T. Clifton; Jarrod P. Holmes; Asna Amin; Mark G. Carmichael; J 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 728 KB

A phase II trial to assess efficacy and

✍ Martin Schuler, Ahmad Awada, Philipp Harter, Jean Luc Canon, Kurt Possinger, Mar 📂 Article 📅 2012 🏛 Springer US 🌐 English ⚖ 303 KB

Safety and immunogenicity of a CTL multi

✍ Paul Spearman; Spyros Kalams; Marnie Elizaga; Barbara Metch; Ya-Lin Chiu; Mary A 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 611 KB

A virosomal formulated Her-2/neu multi-p

✍ Ursula Wiedermann; C. Wiltschke; J. Jasinska; M. Kundi; R. Zurbriggen; E. Garner 📂 Article 📅 2009 🏛 Springer US 🌐 English ⚖ 321 KB

An open-label, prospective phase I/II st

✍ Meyer, Ralf G.; Korn, Stephanie; Micke, Patrick; Becker, Kai; Huber, Christoph; 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 216 KB

Early results of a phase I clinical tria

✍ Steven Khoo; Catherine Storrer; Katie Harris; Yusuf Jama; Anna Smith; Zia Dehqan 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 47 KB